Eficácia e segurança da triancinolona hexacetonida em comparação com plasma rico em plaquetas e minoxidil no tratamento da alopecia areata

##plugins.themes.bootstrap3.article.main##

Larissa Souza de Jesus
João Victor Oinhos de Oliveira
Aline Bragança de Oliveira
Julia Pereato Fernandes
Ana Carolina Cola
Luana de Melo Simmer
Larissy da Silva Maciel
Taíssa Louzada Sandrini
Eduarda Azevedo Pimentel
Priscila de Jesus Santana

Resumo

Objetivo: Avaliar a eficácia e segurança da triancinolona hexacetonida no tratamento da alopecia areata, comparando com outras abordagens terapêuticas e considerando os desfechos clínicos a curto e longo prazo. Métodos: Trata-se de uma revisão integrativa, analisando a população com alopecia areata, exposta a diferentes medicações, sendo elas: triancinolona hexacetonida, PRP ou minoxidil. As buscas foram realizadas no banco de dados PubMed Central (PMC), resultando em um total de 243 artigos, que passaram por um processo de seleção e classificação. Resultados: Os artigos selecionados mostraram que a triancinolona hexacetonida segue como primeira linha de tratamento, embora seja uma medicação de difícil acesso no Brasil. Alternativas comprovadas por inúmeros estudos, como o PRP, foram apresentadas como intervenções efetivas, especialmente quando associadas ao minoxidil tópico. Considerações Finais: Considera-se que a triancinolona é eficaz no tratamento da alopecia areata leve a moderada, mas apresenta efeitos colaterais significativos com o uso prolongado. Terapias emergentes, como o PRP e o minoxidil, oferecem alternativas promissoras, com menos riscos e resultados comparáveis.

##plugins.themes.bootstrap3.article.details##

Como Citar
JesusL. S. de, OliveiraJ. V. O. de, OliveiraA. B. de, FernandesJ. P., ColaA. C., SimmerL. de M., MacielL. da S., SandriniT. L., PimentelE. A., & SantanaP. de J. (2025). Eficácia e segurança da triancinolona hexacetonida em comparação com plasma rico em plaquetas e minoxidil no tratamento da alopecia areata. Revista Eletrônica Acervo Saúde, 25, e19244. https://doi.org/10.25248/reas.e19244.2025
Seção
Revisão Bibliográfica

Referências

1. ALMOHANNA HM, et al. Platelet-rich plasma in the treatment of alopecia areata: a review. Journal of Investigative Dermatology Symposium Proceedings, 2020: S45-S49.

2. ANUDEEP TC, et al. Advancing regenerative cellular therapies in non-scarring alopecia. Pharmaceutics, 2022; 14(3): 612.

3. BALAKRISHNAN A, et al. A comparative study of therapeutic response to intralesional injections of platelet-rich plasma versus triamcinolone acetonide in alopecia areata. Indian dermatology online journal, 2020; 11(6): 920-924.

4. BARLETTA M, GASQUES L. Successful treatment of alopecia areata patches with triamcinolone acetonide using MMP®: report of 2 cases. Skin Appendage Disorders, 2020; 6(4): 229-234.

5. CHU TW, et al. Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: An ntrasubject pilot study. Journal of the American Academy of Dermatology, 2015; 73(2): 338-340.

6. CRUCIANI M, et al. Platelet-rich plasma for the treatment of alopecia: A systematic review and meta-analysis. Blood Transfusion, 2023; 21(1): 24.

7. DE SOUSA VB, et al. Intralesional betamethasone versus triamcinolone acetonide in the treatment of localized alopecia areata: a within-patient randomized controlled trial. Journal of Dermatological Treatment, 2022; 33(2): 875-877.

8. EL TAIEB MA, et al. Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: a trichoscopic evaluation. Dermatologic therapy, 2017; 30(1): e12437.

9. GUPTA AK, et al. Monotherapy for alopecia areata: a systematic review and network meta-analysis. Skin appendage disorders, 2019; 5(6): 331-337.

10. JAFARZADEH A, et al. Regenerative medicine in the treatment of specific dermatologic disorders: a systematic review of randomized controlled clinical trials. Stem Cell Research & Therapy, 2024; 15(1): 176.

11. KHAN FA, et al. Comparative Study Between Intralesional Injection Of Platelet Rich Plasma And Intra Lesional Triamcinolone For The Treatment Of Alopecia Areata. Journal of Ayub Medical College Abbottabad-Pakistan, 2022; 34(4).

12. MARCHITTO MC, et al. Emerging nonsteroid-based procedural therapies for alopecia areata: a systematic review. Dermatologic Surgery, 2019; 45(12): 1484-1506.

13. MARTORA F, et al. Oral minoxidil for chemotherapy-induced alopecia. Skin Appendage Disorders, 2022; 8(6): 508-510.

14. MUHAMMAD A, et al. Comparison of Efficacy of Autologous Platelet Rich Plasma Therapy With 5% Topical Minoxidil Spray in Treating Alopecia Areata: A Head-to-Head Assessment of Novel Approaches. Cureus, 2024; 16(6).

15. POTOTSCHNIG H, MADL MT. Successful treatment of alopecia areata barbae with platelet-rich plasma. Cureus, 2020; 12(4).

16. RAGAB SEM, et al. Platelet-rich plasma in alopecia areata: intradermal injection versus topical application with transepidermal delivery via either fractional carbon dioxide laser or microneedling. Acta Dermatovenerol Alp Pannonica Adriat, 2020; 29(4): 169-173.

17. RINALDI F, et al. Efficacy of postbiotics in a PRP-like cosmetic product for the treatment of alopecia area Celsi: a randomized double-blinded parallel-group study. Dermatology and therapy, 2020; 10: 483-493.

18. RUCHIATAN K, et al. Successful Therapy of Alopecia Universalis Using a Combination of Systemic Methotrexate and Corticosteroids and Topical 5% Minoxidil. Clinical, Cosmetic and Investigational Dermatology, 2022: 127-132.

19. SHIMIZU Y, et al. Regenerative medicine strategies for hair growth and regeneration: A narrative review of literature. Regenerative therapy, 2022; 21: 527-539.

20. STRAZZULLA LC, et al. An overview of the biology of platelet-rich plasma and microneedling as potential treatments for alopecia areata. Journal of Investigative Dermatology, 2017.

21. VAZQUEZ OA, et al. Alopecia areata treated with advanced platelet-rich fibrin using micronization. Plastic and Reconstructive Surgery–Global Open, 2022; 10(1): e4032.

22. WEI F, et al. Effect of minoxidil combined with triamcinolone acetonide on alopecia areata by microneedle injection. Skin Research and Technology, 2024; 30(4): e13713.